Results 101 to 110 of about 2,557 (149)

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study. [PDF]

open access: yesMol Ther
Kwan TT   +11 more
europepmc   +1 more source

Treatment updates in myotonic disorders. [PDF]

open access: yesJ Neurol
Matthews E, Specterman MJ, Mul K.
europepmc   +1 more source

Modified Polycyclic Compounds Rescue Mis-splicing in Myotonic Dystrophy Type 1 Disease Models. [PDF]

open access: yesACS Chem Biol
Frias JA   +22 more
europepmc   +1 more source

Myotonia congenita in a Greek cohort: Genotype spectrum and impact of the CLCN1:c.501C > G variant as a genetic modifier

open access: yes
Introduction/Aims: Myotonia congenita (MC) is the most common hereditary channelopathy in humans. Characterized by muscle stiffness, MC may be transmitted as either an autosomal dominant (Thomsen) or a recessive (Becker) disorder.
Traeger-Synodinos, Joanne   +12 more
core  

Differential pathology and susceptibility to MBNL loss across muscles in myotonic dystrophy mouse models. [PDF]

open access: yesJCI Insight
Davenport ML   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy